Ortho-Clinical Diagnostics HIV assay approval
This article was originally published in The Gray Sheet
Johnson & Johnson unit receives supplemental PMA approval Oct. 13 for its Vitros Anti-HIV 1+2 Assay to run on its Vitros 5600 Integrated and Vitros 3600 Immunodiagnostic platforms. The test is the first HIV assay to be approved for an integrated platform in the U.S., according to the company. Vitros 5600 allows labs to run HIV and other routine assays on a single platform, which eliminates the need for batch testing, the firm noted. Vitros 5600 and Vitros 3600 launched late last year, and since then, the company has released 112 assays for use on the systems. Approval of the complete 114-assay Vitros menu is expected by 2010. During J&J's Oct. 13 third-quarter earnings call, the firm said the addition of the new Vitros platforms has doubled the applicable market for Ortho-Clinical Diagnostics products
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.